ARTICLE | Finance
After promising ASCO readout, Inspirna raises $50M series D
Sands, Vivo lead syndicate after start-up showcases response rates for potential first-in-class therapy in colorectal cancer
July 11, 2022 7:14 PM UTC
Weeks after presenting data at ASCO showing that its lead candidate led to responses in 50% of evaluable KRAS-mutant colorectal cancer (CRC) patients, Inspirna announced a $50 million series D round to support continued clinical work.
Sands Capital and Vivo Capital led the round, with first-time backer Dreavent 6 and several prior investors participating...